ArticleCureus2026
Moderate-Dose Local Radiotherapy in Symptomatic CD30-Positive, Anaplastic Lymphoma Kinase (ALK)-Negative Primary Cutaneous T-cell Lymphoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary cutaneous anaplastic CD30-positive (+) T-cell lymphoma is a rare variant of primary cutaneous lymphoma characterized by proliferation of large T lymphocytes with strong CD30 expression and no anaplastic lymphoma kinase (ALK) expression. It typically presents as rapidly growing nodules or tumors with a tendency to ulcerate, but often has a favorable outcome in localized stages. Radiotherapy is an effective local treatment for cutaneous T-cell lymphomas, and several retrospective studies suggest that low-dose regimens may achieve high response rates with reduced toxicity, although prospective randomized data are lacking. We describe the case of a 65-year-old female patient who initially presented with generalized erythematous patches and plaques that progressed to painful nodules and later ulcerated. Biopsy confirmed a CD30+, ALK-negative, T-cell lymphoma. The patient received chemotherapy with the CHOEP regimen and, during the sixth cycle, developed a new ulcerated lesion on her right thigh accompanied by local signs of infection, leukocytosis, and fever. The patient was then started on antibiotics with no improvement. Localized radiotherapy was then administered, which resulted in progressive improvement of the lesion from the first sessions, with tumor volume reduction, decreased exudate, and partial re-epithelialization of the ulcerated bed. This case highlights the role of localized radiotherapy as an effective palliative and disease-controlling modality for cutaneous CD30+ T-cell lymphoma, particularly in symptomatic or treatment-refractory lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.